MedTrace Logo

MRI-Based Estimation of Lumbar CSF Volume and Its Clinical Impact on Spinal Anaesthesia

NCT07333703 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-01-12

No results posted yet for this study

Summary

This prospective observational study aims to investigate the clinical impact of lumbar cerebrospinal fluid (CSF) volume on spinal anesthesia characteristics. A total of 40 adult patients, aged 18 to 75 years and classified as ASA physical status I-III, who had undergone 3D T2-weighted lumbosacral MRI within the past six months, were enrolled. Intrathecal anesthesia was administered with 4 mL (20 mg) of 0.5% hyperbaric bupivacaine via the L3-L4 interspace in a sitting position.

CSF volume was measured from the lower half of the L1 vertebral body to the sacral end using the volume of interest (VOI) method on sagittal 3D T2-weighted MR images, processed with the ITK-SNAP software. Primary outcome was the correlation between lumbosacral CSF volume and peak sensory block level. Secondary outcomes included correlations with the onset time and duration of sensory and motor block, two-segment regression time, and patient characteristics such as height, weight, BMI, and age.

Conditions

  • Spinal Anaesthesia
  • Magnetic Resonance Imaging (MRI)
  • Lumbosacral Spinal Stenosis
  • Anaesthesia

Interventions

PROCEDURE

Distribution of spinal anesthetic agent

Under aseptic conditions and in a sitting position, a 25G spinal needle was inserted through the midline at the L₃-L₄ intervertebral space, advancing parallel to the dura fibers. Upon clear cerebrospinal fluid (CSF) flow, the needle bevel was oriented cephalad and 20 mg of 0.5% hyperbaric bupivacaine was injected into the intrathecal space. Patients were kept supine for 5 minutes before sensory block was assessed by pinprick test from the midclavicular line. All spinal anesthesia procedures were performed by the same experienced anesthesiologist.

Sponsors & Collaborators

  • Samsun University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-09-01
Completion
2025-11-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07333703 on ClinicalTrials.gov